Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

QL Block Versus EO Plane Block for Analgesia After Open Nephrectomy

NCT07787221 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-04-01
Last updated
2026-09-01

Condition(s) studied

Postoperative Pain

Investigational drug(s) / intervention(s)

Quadratus Lumborum Block (QLB)External Oblique Plane Block

Quadratus Lumborum Block (QLB): Ultrasound-guided transmuscular quadratus lumborum block using 30 mL of 0.25% bupivacaine administered before induction of general anesthesia.

External Oblique Plane Block: Ultrasound-guided external oblique plane block using 30 mL of 0.25% bupivacaine administered before induction of general anesthesia.

Study summary

This prospective randomized clinical trial aims to compare two ultrasound-guided regional anesthesia techniques, the transmuscular quadratus lumborum (QL) block and the external oblique (EO) plane block, for pain relief after open nephrectomy. Open nephrectomy is a major surgical procedure that can cause significant postoperative pain and may require opioid medications for adequate pain control.

Adult patients undergoing open nephrectomy at the National Cancer Institute, Cairo University, who meet the study eligibility criteria will be randomly assigned to receive either a QL block or an EO plane block before surgery. Both techniques will be performed under ultrasound guidance using bupivacaine in addition to standardized general anesthesia and multimodal postoperative analgesia.

The main purpose of the study is to determine whether the QL block provides better postoperative analgesia than the EO plane block. The primary outcome will be the total amount of intravenous morphine consumed during the first 24 hours after surgery. Secondary outcomes will include postoperative pain scores, time to first request for rescue analgesia, hemodynamic changes, recovery time, patient satisfaction, and adverse effects related to analgesia or the regional anesthesia techniques.

A total of 54 patients will be enrolled and randomly allocated equally between the two treatment groups.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
\*\*Inclusion Criteria:\*\* * Adult patients aged 18 to 65 years. * Patients undergoing open nephrectomy at the National Cancer Institute, Cairo University. * American Society of Anesthesiologists (ASA) physical status II-III. * Body mass index (BMI) greater than 20 kg/m² and less than 35 kg/m². \*\*Exclusion Criteria:\*\* * Patient refusal to participate. * ASA physical status IV. * Age less than 18 years or greater than 65 years. * BMI less than 20 kg/m² or greater than 35 kg/m². * Known allergy or contraindication to any study medication, including local anesthetics or opioids. * History of psychiatric disorders or chronic pain. * Contraindications to regional anesthesia, including local infection at the injection site, pre-existing neuropathy, or coagulopathy. * Severe organ dysfunction, including cardiac dysfunction (ejection fraction \<40%), respiratory dysfunction (FEV1 \<50% of predicted or requirement for home oxygen therapy), hepatic dysfunction (Child-Pugh class C), or renal dysfunction (estimated glomerular filtration rate \<30 mL/min/1.73 m²).

Primary outcome measure(s)

  • 24-hour postoperative morphine consumption — First 24 hours after surgery
    Total amount of intravenous morphine administered as rescue analgesia during the first 24 hours after surgery. Morphine consumption will be recorded for each participant and compared between the quadratus lumborum block and external oblique plane block groups.

Trial sites (2)

FacilityCityRegionStatus
Cairo University Cairo Egypt Recruiting
Cairo University Cairo Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07787221 on ClinicalTrials.gov ↗ ← All trials in Egypt